Sun.May 29, 2022

article thumbnail

1 million youth became daily tobacco users, most used juul e-cigarettes

Scienmag

More than 1 million United States youth aged 14 to 17 years old in 2017 became new daily tobacco users within two years. By 2019, more than three quarters of these youths were vaping e-cigarettes daily. Credit: University of California San Diego More than 1 million United States youth aged 14 to 17 years old […].

84
article thumbnail

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

pharmaphorum

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held by Merck & Co’s rival Keytruda. The pair of new approvals are based on the results of the CheckMate-648 trial, and are for Opdivo (nivolumab) paired with chemotherapy or BMS’ CTLA4 inhibitor Yervoy (ipilimumab) as first-line therapy for advanced or metastatic oesophageal squamous cell carc

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A new ultra-thin electrode material: A step closer to next-generation semiconductors

Scienmag

To realize artificial intelligence systems and autonomous driving systems, which is often seen in movies, in everyday life, processors that function as the brain of computers must be able to process more data. However, silicon-based logic devices, which are essential components of computer processors, have limitations in that processing costs and power consumption increase as […].

article thumbnail

New patent expiration for Glaxosmithkline drug ADVIL PM

Drug Patent Watch

Annual Drug Patent Expirations for ADVIL+PM Advil Pm is a drug marketed by Glaxosmithkline and is included in two NDAs. It is available from four suppliers. There are three patents…. The post New patent expiration for Glaxosmithkline drug ADVIL PM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Residents of Ontario retirement home residences have higher rates of hospital care than residents of long-term care homes

Scienmag

Residents of retirement homes in Ontario have high rates of hospital-based care compared to residents in long-term care (LTC) facilities and to people living in the community, found new research published in CMAJ (Canadian Medical Association Journal) [link] Retirement homes are generally privately run, for-profit residences to support independent living for older people thought to […].

article thumbnail

A Balm for Psyches Scarred by War

NY Times

MDMA-assisted treatment for post-traumatic stress disorder “represents real hope for long-term healing,” health experts say.

article thumbnail

Which pharmaceutical companies have the most SPCs in Spain?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

52